Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 ASCO Annual Meeting 2013 Poster presentation January 2013.

Published byCandice Doyle Modified over 9 years ago

Similar presentations

Presentation on theme: "1 ASCO Annual Meeting 2013 Poster presentation January 2013."— Presentation transcript:

1 1 ASCO Annual Meeting 2013 Poster presentation January 2013

2 2 5 years results: 734 patients, 7 centres in Germany Absolute number of events in TARGIT vs. EBRT : Primary outcome: IBR 4 vs. 1 Exploratory outcome: All recurrences (breast +axilla+contralateral+distant recurrence) 11 vs. 7 Secondary outcome: All deaths 6 vs. 12 Breast Cancer deaths 3 vs. 5 Non-Breast Cancer deaths 3 vs. 7 Message: The 734 German patients have excellent 5 year outcomes in both arms of the trial Survival was better in TARGIT than in EBRT Source: J Clin Oncol 31, 2013 (suppl; abstr 1121) TARGIT-A trial: Updated results for local recurrence and survival for the German centers Presenter: Frederik K. Wenz January 2013

3 3 Matched pair analysis impact on overall survival of IORT boost vs. EBRT boost : 370 patients with 53 pairs Medium Follow up: 56 month in IORT vs. 6 month in EBRT Strong trend towards better overall survival after IORT boost (90.2% vs. 62.3%, p = 0.375) IBR 1 vs. 1 Message: IORT given as a boost seems to have a positive impact on overall survival in breast cancer patients after breast conserving surgery Source: J Clin Oncol 31, 2013 (suppl; abstr 1120) Intraoperative versus external beam boost for breast cancer: A matched-pair analysis Presenter: Elena Sperk January 2013

4 4 Single center experience since 2006 IORT only vs. WBRT in low risk early breast cancer patients (in patients with high risk tumor characteristics at final pathology, additional local breast therapy) 400 patients Medium Follow up: 30 month (43 months in the first 200 patients) Seven ipsilateral breast failures (1.7%) and one axillary recurrence were observed Message: Center concludes that intraoperative radiotherapy using the Intrabeam system is feasible and may offer an alternative to whole breast RT in low risk breast cancer patients Clinically significant local morbidity rate is low Source: J Clin Oncol 31, 2013 (suppl; abstr 1108) Intraoperative radiotherapy in early breast cancer: 400 consecutive patients in one institution Presenter: Mariana Steiner January 2013

5 5

Download ppt "1 ASCO Annual Meeting 2013 Poster presentation January 2013."

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
13th Annual Hematology & Breast Cancer Update Update in Lymphoma

13th Annual Hematology & Breast Cancer Update Update in Lymphoma
Joint Hospital Surgical Grand Round Accelerated partial breast irradiation: where should we go? Dr Ma Kwok Kuen Queen Mary Hospital.

Joint Hospital Surgical Grand Round Accelerated partial breast irradiation: where should we go? Dr Ma Kwok Kuen Queen Mary Hospital.
2-6-20151 Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June 2 2008, McCormick.

Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.
Breast Cancer Screening, Family History Assessment and New Innovations Miss Karina Cox Consultant Breast and Oncoplastic Surgeon.

Breast Cancer Screening, Family History Assessment and New Innovations Miss Karina Cox Consultant Breast and Oncoplastic Surgeon.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Hot topics in breast radiotherapy Mark Beresford.

Hot topics in breast radiotherapy Mark Beresford.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Study Of Letrozole Extension

Study Of Letrozole Extension
Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.

Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.
These slides were released by the speaker for internal use by Novartis.

These slides were released by the speaker for internal use by Novartis.
Neoadjuvant versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis Mauri D, Pavlidis N, Ioannidis J. J Natl Cancer Inst 2005;97(3):188-94.

Neoadjuvant versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis Mauri D, Pavlidis N, Ioannidis J. J Natl Cancer Inst 2005;97(3):
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,18 1376-1383. 2003.

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Controversies in Radiation Therapy for Breast Cancer?

Controversies in Radiation Therapy for Breast Cancer?
The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.

The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

Similar presentations

Ads by Google